All sponsors

Acerta Pharma BV

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS11
PHASE 3 / 2-35
RECRUITING0
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO91%

Delay Index: of 11 active trials registered more than a year ago, 10 have moved their primary completion (readout) date by more than 6 months since first registration (median +49.0 months). See all sponsors →

Open Acerta Pharma BV on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Acalabrutinib (ACP-196)
NCT02180724
P2Active, not recruitingWaldenström Macroglobulinemia (WM)1072019-10-01 (+49 mo)
ACP-196
NCT02586857
P1/2Active, not recruitingGlioblastoma Multiforme242020-06-26 (+30 mo)
Acalabrutinib
NCT02477696
P3Active, not recruitingChronic Lymphocytic Leukemia5332020-09-15 (+27 mo)
ACP-196 (acalabrutinib)
NCT02717611
P2Active, not recruitingChronic Lymphocytic Leukemia602020-10-16 (+8 mo)
ACP-196 (acalabrutinib)
NCT02213926
P2Active, not recruitingMantle Cell Lymphoma (MCL)1242020-12-04 (+61 mo)
Acalabrutinib
NCT02029443
P1/2Active, not recruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma3062021-07-15 (+66 mo)
Acalabrutinib (ACP-196)
NCT02970318
P3Active, not recruitingChronic Lymphocytic Leukemia3102021-09-03 (+20 mo)
acalabrutinib
NCT02180711
P1/2Active, not recruitingNon Hodgkin Lymphoma1132023-08-25 (+96 mo)
Acalabrutinib
NCT02972840
P3Active, not recruitingLymphoma, Mantle Cell6352027-02-15 (+52 mo)
ESCALADE
NCT04529772
P3Active, not recruitingDiffuse Large B-Cell Lymphoma6112027-02-22 (+6 mo)
AMPLIFY
NCT03836261
P3Active, not recruitingChronic Lymphocytic Leukemia9842027-04-30 (+56 mo)